GeneCentric Therapeutics: Funding, Investors & Team (Oct 2026)
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
GeneCentric Therapeutics has raised $10.0M across 2 funding rounds on record, the most recent a Convertible Note of $2.5M announced in Sep 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GeneCentric Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
GeneCentric Therapeutics Funding Rounds
GeneCentric Therapeutics raised $7.5M in a Series B announced in Nov 2021.
10 months later, a Convertible Note of $2.5M was announced in Sep 2022.
GeneCentric Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
GeneCentric Therapeutics Funding Compared to Other Biotechnology Startups
GeneCentric Therapeutics' latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GeneCentric Therapeutics in Biotechnology and Durham
Companies Similar to GeneCentric Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
GeneCentric Therapeutics Funding FAQs
What does GeneCentric Therapeutics do?
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
How much funding has GeneCentric Therapeutics raised?
GeneCentric Therapeutics has raised $10.0M across 2 rounds on record. The most recent is a Convertible Note of $2.5M announced in Sep 2022.
When did GeneCentric Therapeutics last raise funding?
GeneCentric Therapeutics' most recent funding round on record is a Convertible Note of $2.5M, announced in Sep 2022.
Who is the CEO of GeneCentric Therapeutics?
Michael Milburn is listed as CEO at GeneCentric Therapeutics.
Where is GeneCentric Therapeutics headquartered?
GeneCentric Therapeutics is based in Durham, North Carolina, United States.
How many employees does GeneCentric Therapeutics have?
GeneCentric Therapeutics is in the 11-50 employee band.
How does GeneCentric Therapeutics' funding compare to other Biotechnology startups?
GeneCentric Therapeutics' latest round of $2.5M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's GeneCentric Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GeneCentric Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.